Bavarian Nordic A/S, of Copenhagen, completed the acquisition of the manufacturing and global rights to the two commercial vaccines, Rabipur/Rabavert and Encepur, from London-based Glaxosmithkline plc (GSK), disclosed in October. Bavarian paid GSK €307.6 million (US$345.2 million). The amount has been adjusted by €6.6 million due to variance between the currently and the previously estimated inventory at Dec. 31, 2019, the companies said. 

Gemphire Therapeutics Inc., of Ann Arbor, Mich., said the pending merger with Neurobo Pharmaceuticals Inc., of Boston, was expected to close after market hours Tuesday, subject to satisfaction or waiver of all closing conditions. As previously disclosed, Gemphire’s stockholders voted to approve the proposals required to complete the deal.  

Johnson & Johnson, of New Brunswick, N.J., said its Janssen business completed the acquisition of all rights to bermekimab, which has multiple dermatological indications, along with certain employees, from Xbiotech Inc., of Austin, Texas, for $750 million. Should Janssen pursue bermekimab indications outside of dermatology, Xbiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. Janssen Research & Development LLC will develop bermekimab.  

Eli Lilly and Co., of Indianapolis, said the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta (pemetrexed for injection) vitamin regimen patent would be infringed by a competitor that had stated its intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022. The ruling came in the case of Lilly vs. Apotex Inc., of Toronto. 

Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said the U.S. District Court for the Southern District of New York ruled on several motions related to Navidea and its majority-owned subsidiary, Macrophage Therapeutics Inc. (MT), and Michael Goldberg that substantially limited the claims that Goldberg can pursue against Navidea and MT. The court found that certain portions of Goldberg’s counterclaims against Navidea and third-party claims against MT failed to state a claim upon which relief can be granted. Specifically, the court ruled that actions taken by Navidea and MT, including reconstituting the MT board, replacing Goldberg with Jed Latkin as CEO, terminating the sublicense between Navidea and MT, terminating certain research projects, and allowing MT intellectual property to revert back to Navidea, were not breaches of an August 2018 agreement among Navidea, MT and Goldberg. 

Vivus Inc., of Campbell, Calif., said its board adopted a new stockholder rights plan to replace the company’s stockholder rights plan that expired in accordance with its terms in November. Under the new plan, the terms of which are substantially similar to the previous one, Vivus will issue a dividend of one right for each share of its common stock held by stockholders of record as of the close of business on Jan. 13, 2020. The new rights plan is designed to protect stockholder value by mitigating the likelihood of an ownership change that would result in significant limitations on the company’s ability to use its net operating losses or other tax attributes to offset future income, Vivus said. 

No Comments